Introducing I-FABP on clinical routine would stimulate the development of a point of care approach, as it was already developed for H–FABP, with a bedside test with available results within 15 min for acute coronary syndrome or myocardial infarction [19]. The gene discussed is FABP2; the disease is myocardial infarction.